Pre-Op Chronic Opioid Use Ups Poor Outcomes Post Spinal Fusion

Share this content:
Pre-Op Chronic Opioid Use Ups Poor Outcomes Post Spinal Fusion
Pre-Op Chronic Opioid Use Ups Poor Outcomes Post Spinal Fusion

MONDAY, April 2, 2018 (HealthDay News) -- Preoperative chronic opioid use is associated with poor outcomes and continued dependence after posterior lumbar fusion, according to a study published online March 20 in Spine.

Nikhil Jain, M.D., from The Ohio State University in Columbus, and colleagues used commercial insurance data (from 2007 to Q3-2015) to evaluate preoperative opioid use in 24,610 patients undergoing primary one- and two-level posterior lumbar fusion. The authors also assessed associated 90-day complications, emergency department visits, readmissions, one-year adverse events, and costs.

The researchers found that 22.3 percent of patients had documented opioid use for more than six months before surgery, and 87.4 percent of these had continued long-term use postoperatively. Preoperative chronic opioid use was associated with higher risk for 90-day wound complications, pain diagnoses, emergency department visits, readmission, and continued postoperative use. Additionally, one year after surgery, long-term opioid users had an increased risk for epidural/facet joint injections, revision fusion, and new onset constipation.

"Preoperative chronic opioid therapy is a modifiable risk factor for complications, readmission, adverse events, and increased costs after one- and two-level posterior lumbar fusion," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

CDC: Birth Rate for 10- to-14-Year-Olds at Record Low in 2016

CDC: Birth Rate for 10- to-14-Year-Olds at Record ...

Reduction in birth rates for all race and Hispanic origin groups; largest decline in non-Hispanic blacks

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria

Lower mortality seen with lonafarnib monotherapy after 2.2 years compared with no treatment

About 40 Percent of Men Report Experiencing Weight Stigma

About 40 Percent of Men Report Experiencing Weight ...

Experience of weight stigma associated with increased odds of underweight or obesity

is free, fast, and customized just for you!

Already a member?

Sign In Now »